Search

Filter Options

Active Development

Reset

Delivery Type

Reset

Duration Type

Reset

Developer

Reset

User

Reset

Hormonal

Reset

Development Stage

Reset

Potential MPT

Reset

API

Reset
View by user and type (hormonal or non-hormonal)
Displaying 121 - 130 of 243
Alternative Name: Levonorgestrel Gastric Resident Dosage Form, Levonorgestrel Gastric Retentive Dosage Form
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral
Developer: Lyndra Therapeutics, Massachusetts Institute of Technology
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Levonorgestrel (LNG) Intracervical Device (ICD)
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Vaginal, Other
Developer: University of Helsinki, Population Council
Development Stage: Phase I
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Levonorgestrel (LNG)-only patch; AG890
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: Agile Therapeutics
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: One-year LNG Single Rod Implant
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: CONRAD, FEI Technologies
Development Stage: Phase I
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable, Subdermal
Developer: Orbis Biosciences
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: FHI 360
Development Stage: Phase I
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: (3β,13ξ)-Lup-20(29)-en-3-ol; Clerodol; Monogynol B; Fagarasterol; Farganasterol
User: Female, Male
Hormonal: No
Duration Type: Short-acting, Pericoital
Delivery Method: Oral, Other
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Merck
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: No
Duration Type: Emergency
Delivery Method: Oral
Developer: CONRAD
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: No
Delivery Method: Vaginal Ring
Developer: Andromaco
Development Stage: Phase I
Development Phase: Pre-Clinical and Clinical Development

Pages

Displaying 1 - 10 of 70
Alternative Name: 11b-methyl-19-nortestosterone 17b-dodecylcarbonate (11b-MNTDC)
User: Male
Hormonal: Yes
Delivery Method: Injectable, Oral
Developer: BIOQUAL, Inc.
Development Stage: Lead Optimization
Alternative Name: Abhydrolase Domain Containing 2, 2-Arachidonoylglycerol Hydrolase, Monoacylglycerol Lipase ABHD2, Lung Alpha/Beta Hydrolase 2, Protein PHPS1-2, LABH2, Alpha/Beta Hydrolase Domain Containing Protein 2
Target
Hormonal: No
Development Stage: Target Validation
Alternative Name: Acrosomal Vesicle Protein 1, Acrosomal Protein SP-10, Sperm Protein 10, D11S4365, SPACA2, SP-10
Target
User: Female
Hormonal: No
Development Stage: Target Validation
Alternative Name: GnRH II Receptor Antagonists
Hormonal: Yes
Developer: CICRR, San Antonio, CONRAD
Development Stage: Compound ID/Selection
Alternative Name: ADAM Metallopeptidase Domain 2, Fertilin β, Cancer/Testis Antigen 15, Disintegrin And Metalloproteinase Domain-Containing Protein 2, PH30-Beta, FTNB, CT15, PH30, EC 3.4.24, PH-30b, CRYN1, CRYN2, PH-30
Target
User: Female, Male
Hormonal: No
Development Stage: Target Validation
Alternative Name: Adenylate Cyclase 10 and cyclic adenosine monophopshate, sAC and cAMP, soluble adenylyl cyclase
Target
User: Female, Male
Hormonal: No
Development Stage: Target Validation
Alternative Name: Androglobin, Calpain-7-Like Protein, C6orf103, Chromosome 6 Open Reading Frame 103, CAPN16, CAPN7L
Target
User: Female, Male
Hormonal: No
Development Stage: Target Identification
Alternative Name: AF-2364
User: Female, Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Injectable, Oral, Other
Developer: Population Council
Development Stage: Lead Optimization
Alternative Name: Mullerian-inhibiting Substance (MIS), Mullerian-inhibiting Hormone (MIH), Mullerian-inhibiting Factor (MIF), Mullerian Duct Inhibitory Factor (MDIF), Mullerian Regression Factor (MRF), Anti-paramesonephric Hormone (APH)
Development Stage: Lead Optimization
Alternative Name: Astacin Like Metalloendopeptidase, Ovastacin, Sperm Acrosomal SLLP1 Binding, SAS1B, Oocyte Astacin, EC 3.4
Target
User: Female
Hormonal: No
Development Stage: Target Validation

Pages

Displaying 61 - 70 of 121
User: Female
Hormonal: No
Duration Type: Emergency
Delivery Method: Oral
Developer: CONRAD
Development Stage: Phase II
User: Female
Hormonal: No
Delivery Method: Vaginal Ring
Developer: Andromaco
Development Stage: Phase I
Alternative Name: MENT Transdermal Gel
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: Population Council
Development Stage: Phase I
Alternative Name: MENT Acetate Implant, 7α-methyl-19-nortestosterone
User: Male
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Population Council
Development Stage: Phase II
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: 7Med Industrie, France
Development Stage: Regulatory
Alternative Name: MAP, Microneedle Patch
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Other
Developer: PATH, Queen's University Belfast, ViiV Healthcare, Population Council, LTS Lohmann Therapie-Systeme AG
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: FHI 360, University of Washington
Development Stage: Pre-clinical
Alternative Name: MZCL Combination IVR
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: Population Council, ProMed Pharma
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Delivery Method: Subdermal
Developer: Shandong University
Development Stage: Pre-clinical
Alternative Name: Nestorone (NES) + Estradiol (E2) Vaginal Ring
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: NICHD, Population Council
Development Stage: Phase II

Pages

Displaying 21 - 30 of 52
Alternative Name: GyneFix 330
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Shenyang Liren Medical & Technological Co.
Development Stage: Marketed
Alternative Name: Copper IUD for Nulliparous Women, Smaller Copper IUD T380
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Implementos Plasticos, Ltd., Mexico City
Development Stage: SRA/WHO PQ Approved
Alternative Name: SCu300 Intrauterine Devices, empira™
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: OCON Medical Ltd.
Development Stage: SRA/WHO PQ Approved
Alternative Name: LNG Contraceptive IUS (LCS); LCS16
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Bayer HealthCare
Development Stage: SRA/WHO PQ Approved
Alternative Name: Zarin; Femplant; Trust; Sino-implant (II)
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: FHI 360, Shanghai Dahua Pharmaceuticals, Ltd.
Development Stage: Marketed
Alternative Name: Levosert (U.K.); Erlacela (Portugal); Donasert (Romania); Avibela
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Actavis, Medicines360
Development Stage: SRA/WHO PQ Approved
Alternative Name: FC-Patch Low; Gestodene (GES) + ethinyl estradiol (EE) Patch
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: WHO HRP, Bayer HealthCare, Gedeon Richter Plc.
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: 7Med Industrie, France
Development Stage: Regulatory
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Mona Lisa N.V.
Development Stage: SRA/WHO PQ Approved

Pages

CSV